Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves Β· freshest Wall Street data, updated daily View live feed β†’
Analyst Tracker/Boobalan Pachaiyappan
ROTH

Boobalan Pachaiyappan

Wall Street Analyst
β˜…β˜†β˜†β˜†β˜†
#3044
on 13Foresight Β· ranked by our own returns
38%
Success Rate
-11.8%
Average Return
24 of 64 calls profitable Β· -13.5% vs benchmark
S&P 500 (SPY)
πŸ“ˆ Across the calls we could measure, roughly 38% of Boobalan Pachaiyappan's ratings turned a profit when each position was held for 1 year β€” averaging -11.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

100 Buy 6 Hold 0 Sell
Boobalan's Stock Coverage 28 ratings Β· 2026-11-17
Company Date Position Consensus β“˜ Price Target β“˜ 1-Yr Return vs S&P 500 β“˜
PYPD
PolyPid
Oct 29, 2026 BUY Strong Buy
+191.6% avg upside
7 analysts
$8.00
48.41% Upside
+17.0% Β·
RNA
Atrium Therapeutics, Inc.
Oct 22, 2026 BUY Strong Buy
+246.6% avg upside
6 analysts
$15.00
81.35% Upside
-21.2% Β·
COYA
Coya Therapeutics, Inc.
Oct 15, 2026 BUY Strong Buy
+343.2% avg upside
7 analysts
$12.00
232.48% Upside
-30.4% Β·
NRSN
Neurosense Therapeutics Ltd.
Oct 13, 2026 HOLD Strong Buy
+4265.6% avg upside
5 analysts
$3.50
75.97% Upside
-49.6% Β·
CRVO
CervoMed
Oct 13, 2026 BUY Strong Buy
+1040.3% avg upside
9 analysts
$7.00
337.59% Upside
-19.4% Β·
CAPR
Capricor Therapeutics
Oct 06, 2026 HOLD Strong Buy
+332.5% avg upside
12 analysts
$7.00
9.77% Upside
+8.5% Β·
CH:NWRN
Newron Pharmaceuticals SpA
Oct 05, 2026 BUY Strong Buy
+203.1% avg upside
4 analysts
$19.00
111.14% Upside
+12.0% Β·
LBRX
LB Pharmaceuticals, Inc.
Oct 05, 2026 HOLD Strong Buy
+47.7% avg upside
11 analysts
$35.00
11.79% Downside
+16.4% Β·
MNOV
Medicinova
Sep 19, 2026 BUY Strong Buy
+411.9% avg upside
6 analysts
$6.00
328.62% Upside
-59.4% Β·
ABEO
Abeona Therapeutics
Sep 19, 2026 BUY Strong Buy
+295.1% avg upside
18 analysts
$17.00
290.78% Upside
-54.5% Β·
ANVS
Annovis Bio
Sep 04, 2026 BUY Strong Buy
+1922.3% avg upside
8 analysts
$7.00
519.44% Upside
-46.8% Β·
OVID
Ovid Therapeutics
Sep 03, 2026 BUY Strong Buy
+103.8% avg upside
19 analysts
$8.00
214.95% Upside
-20.1% Β·
IMUX
Immunic
Sep 01, 2026 BUY Strong Buy
+399.8% avg upside
23 analysts
$29.00
286.18% Upside
-49.7% Β·
CING
Cingulate Inc
Aug 24, 2026 BUY Strong Buy
+306.6% avg upside
5 analysts
$9.00
80.74% Upside
-24.3% Β·
PMN
ProMIS Neurosciences
Aug 21, 2026 BUY Strong Buy
+1862.7% avg upside
9 analysts
$29.00
776.20% Upside
-77.9% Β·
LGVN
Longeveron
Aug 19, 2026 BUY Strong Buy
+4590.7% avg upside
4 analysts
$30.00
1696.49% Upside
-65.5% Β·
GANX
Gain Therapeutics
Aug 18, 2026 BUY Strong Buy
+596.9% avg upside
9 analysts
$8.00
607.95% Upside
-42.4% Β·
TRDA
Entrada Therapeutics Inc
Aug 12, 2026 BUY Strong Buy
+370.4% avg upside
10 analysts
$11.00
142.53% Upside
-35.3% Β·
RVPH
Reviva Pharmaceuticals Holdings
Apr 01, 2026 BUY Strong Buy
+12423.8% avg upside
9 analysts
$1.00
185.69% Upside
-52.0% Β·
ENSC
Ensysce Biosciences
May 20, 2024 HOLD Buy
+1919.0% avg upside
4 analysts
β€” Β· Β·
BWAY
Brainsway
May 20, 2024 HOLD Strong Buy
+25.4% avg upside
10 analysts
β€” +94.9% Β·
SPRB
Spruce Biosciences
May 20, 2024 HOLD Strong Buy
+130.2% avg upside
16 analysts
β€” Β· Β·
ANEB
Anebulo Pharmaceuticals
May 20, 2024 HOLD Buy
+1289.6% avg upside
5 analysts
β€” -53.0% Β·
PXMD
PaxMedica, Inc.
May 20, 2024 HOLD Hold
1 analyst
β€” Β· Β·
TSE:CSCI
COSCIENS Biopharma
May 20, 2024 HOLD Strong Buy
+102.4% avg upside
8 analysts
β€” Β· Β·
RKTO
Rocket One
May 20, 2024 HOLD Strong Buy
+2130.8% avg upside
8 analysts
β€” -29.5% Β·
DMRA
Damora Therapeutics
Oct 24, 2023 HOLD Strong Buy
+39.9% avg upside
20 analysts
β€” -48.8% Β·
OBX
Obsidian Therapeutics
Sep 19, 2023 HOLD Strong Buy
+14.6% avg upside
11 analysts
$0.30
97.99% Downside
Β· Β·
πŸ”’ 23 more ratings β€” with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Boobalan Pachaiyappan β€” Frequently Asked Questions
How accurate are Boobalan Pachaiyappan's stock ratings?
Based on the calls 13Foresight could measure, about 38% of Boobalan's ratings were profitable over a one-year hold, with an average return of -11.2% per rating, or -12.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Boobalan ranked on 13Foresight?
Boobalan Pachaiyappan is currently ranked #3044 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge β€” so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Boobalan cover?
Boobalan most recently has ratings on PYPD, RNA, COYA, NRSN, CRVO, CAPR, CH:NWRN, LBRX, MNOV, ABEO, ANVS, OVID and 16 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.